Fig 5. Antiviral activity of drug combinations against Makona variant of Ebola virus.

Dose matrix (6 x 6) evaluation of two drug combinations, lamivudine/toremifene citrate and lamivudine/zidovudine. Huh 7 cells were pre-treated with drug combinations for 1 h and inoculated at a multiplicity of infection (MOI) of 0.1 for 72 h. (A) The heat map of percent response shows the antiviral activity of each combination (100% corresponds to “no activity”). (B) The ΔBliss plot indicates how much a combination effect differs from the additive effect as determined by the Bliss model. The experiment was run once with triplicate wells per dose (mean ± SD; n = 3). ΔBliss = 0 (additive effect); ΔBliss <0 (synergistic effect); ΔBliss >0 (antagonistic effect).